AstraZenca Reports Results of Fasenra (benralizumab) in P-lllb PONENTE Trial for Asthma

 AstraZenca Reports Results of Fasenra (benralizumab) in P-lllb PONENTE Trial for Asthma

AstraZenca Reports Results of Fasenra (benralizumab) in P-lllb PONENTE Trial for Asthma

Shots:

  • It is based on P-lllb PONENTE trial assessing Fasenra (benralizumab, 30mg) in adult patients with severe Asthma on high-dose ICS + LABA and long-term use of OCS therapy with or without additional asthma controller. This study included approx. 600 patients in EU, North America, South America, and Taiwan
  • Results: 62% of patients achieved complete elimination of daily OCS use on 1EP and on the 2EP, 81% of patients achieved complete elimination or were able to reduce their daily OCS dose to 5mg or less when further reduction was not possible due to adrenal insufficiency
  • Fasenra is mAb that binds directly to IL-5 receptor alpha on eosinophils and attracts natural killer cells to induce rapid and near-complete depletion of eosinophils via apoptosis. It is currently approved as an add-on maintenance treatment for severe eosinophilic asthma and is approved for self-administration in the US, EU and other countries

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: Fox News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post